钍试剂线扫极谱分析法测定蛋白质的研究

在0.2 mol/L pH 3.0的Britton-Robinson(B-R)缓冲溶液中,钍试剂于-0.49 V(vs.SCE)产生一个灵敏的线性扫描二阶导数极谱还原峰。当在上述溶液中加入人血清白蛋白(HSA)后,钍试剂在-0.49 V处的峰电流降低,而峰电位基本没有变化,这是由于HSA与钍试剂会发生结合反应,使溶液中游离的钍试剂浓度降低,相应的还原峰电流也降低。对结合反应条件和电化学测定条件进行了优化。在最佳条件下,峰电流的降低值同HSA的浓度在1.0~12.0 mg/L范围内呈线性关系。将本法应用于人血清样品的测定所得结果同考马斯亮蓝G-250光度法一致。此方法还可应用于牛血清白蛋白、卵清白蛋白等蛋白质的测定。     

高效迎头分析法测定药物-人血清白蛋白混合液中游离药物浓度

 用高效迎头分析法 (HPFA)测定了药物 人血清白蛋白 (HSA)混合液中游离药物的浓度。样品溶液不经任何处理直接进样到装有内表面反相固定相的色谱柱中 ,用 67mmol/L磷酸盐缓冲液 ( pH 7 4 ,I =0 17mol/L)作流动相。当进样体积足够大时 ,游离药物以平顶峰的形式被洗脱出来 ,平顶峰区域洗脱液中的药物浓度等于样品溶液中游离药物的浓度。收集平顶峰区域的洗脱液 ,然后将一定体积的洗脱液注入到反相色谱柱中 ,测定游离药物的浓度。用该法测定酮基布洛芬 HSA和头孢哌酮 HSA两种混合液中游离药物的浓度。     

PAN-蛋白质络合物的极谱吸附波及其应用

在0.05 mol/L HAc溶液中,PAN-牛血清白蛋白/人血清白蛋白络合物在-0.58 V(vs.SCE)处产生一灵敏吸附还原峰,峰电位较之游离PAN还原峰负约0.28 V,峰电流与牛血清白蛋白、人血清白蛋白浓度在0.1～12 mg/L,0.1～11 mg/L范围内呈线性关系;检测限均为0.05 mg/L。运用该法测定了人血清样品蛋白质含量。     

酸性铬蓝K-蛋白质结合反应体系的极谱分析

酸性铬蓝K(ACBK)在pH3.0Britton Robinson(B R)缓冲溶液中,于-0.41V(vs.SCE)产生一个灵敏的线性扫描二阶导数极谱峰。当在上述溶液中加入人血清白蛋白(HSA)后,由于HSA带正电,而ACBK带负电,两者之间主要通过静电引力形成一种超分子复合物,该复合物无电化学活性,使ACBK在溶液中的游离浓度降低,相应其在-0.41V处的极谱峰电流降低。优化了结合反应的条件和电化学测定条件。在最佳条件下,峰电流的降低值与HSA的加入量在3.0～20.0mg·L-1范围内呈线性关系,应用于人血清样品的测定,试验结果同考马斯亮蓝光度法一致。     

药物间置换相互作用的毛细管电泳-迎头分析法研究

将18-甲基炔诺酮加到人血清白蛋白-酮洛芬平衡溶液中,室温孵育达平衡后应用毛细管电泳-迎头分析法研究了18-甲基炔诺酮和酮洛芬在人血清白蛋白分子上的置换相互作用。一大体积样品虹吸进样至未涂层毛细管(65 cm×50 μm i.d.,有效长度35 cm),进样时间80 s,毛细管两端高度差11 cm,工作电压10 kV,运行缓冲液为67 mmol/L磷酸盐缓冲液(pH 7.4),游离酮洛芬浓度由前沿峰的高度直接测定。当酮洛芬样品溶液中酮洛芬的总浓度分别为100 μmol/L和200 μmol/L时,随着18-甲基炔诺酮加入量的增加(18-甲基炔诺酮的浓度由0增至200 μmol/L),游离酮洛芬的浓度分别从22.4 增至26.4 μmol/L和从82.1增至106.2 μmol/L。由上面的结果可推论:高浓度的18-甲基炔诺酮可将酮洛芬从它的第二类结合位点上置换出来。     

变色酸2B线性扫描伏安法测定血清白蛋白

用线性扫描伏安法研究了在pH3．0的Britton-Robinson(B-R)缓冲溶液中变色酸2B与蛋白质反应前后的电化学变化。在酸性溶液中变色酸2B在-0．48V(us．SCE)处有一个灵敏的伏安还原峰,当在溶液中加入人血清白蛋白后能够发生相互作用形成生物超分子复合物,使变色酸2B的伏安还原峰峰电流下降而峰电位基本保持不变。优化了结合反应条件和电化学测定条件,考察了常见干扰物质对测定的影响。在最佳条件下,峰电流的下降值同人血清白蛋白(HSA)的浓度在2．0～25．0mg／L范围内呈良好的线性关系,线性回归方程为△ip″(nA)=50．56ρ(mg／L)-6．72,相关系数r为0．995,检出限为1．84mg／L。将该方法应用于实际人血清样品的测定,结果与经典的考马斯亮蓝G-250光度法一致,回收率令人满意。     

以茜素兰S为电化学探针测定DNA的研究

在pH 4.5的0.2 mol/L Britton-Robinson(B-R)缓冲溶液中,茜素兰S(ABS)于-0.51 V(vs.SCE)产生一个灵敏的线性扫描二阶导数极谱还原峰。当在上述溶液中加入DNA后,茜素兰S在-0.51 V处还原峰的峰电流降低并且峰电位正移,说明两者之间可以通过嵌插作用而结合。结合反应的发生使溶液中游离的茜素兰S浓度降低,相应的还原峰电流降低。实验优化了结合反应条件和电化学测定条件。在最佳条件下,峰电流的降低值同DNA的浓度在1.0~60.0 mg/L范围内呈线性关系,线性回归方程为△ip″(nA)=18.13c(mg/L)-7.61(n=9,r=0.998)。方法应用于合成样品中DNA的测定,结果令人满意。     

在线固相萃取-高效液相色谱法同时测定人血清中氯氮平、奎硫平和利培酮的含量

使用双梯度液相色谱系统紫外检测器,建立了在线固相萃取液相色谱法全自动、快速、同时测定人血清中氯氮平、奎琉平和利培酮的含量。本方法采用了反相系统,为了提高分离的互补性,使用Capcell MF Ph-1柱作为在线固相萃取柱,Acclaim C18柱作为分析柱。在线固相萃取柱以乙腈-水体系作为流动相,流速1 m L/min梯度洗脱;分析柱以乙腈-100 mmol/L醋酸铵溶液作为流动相,流速1 m L/min,梯度洗脱。样品溶液注入到在线固相萃取苯基柱中,根据此柱的限进机制,血清中的蛋白等大分子物质不被保留而排出,而氯氮平、奎琉平和利培酮等小分子化合物得到保留;通过阀切换使用双梯度液相色谱系统的分析泵将固相萃取柱上保留的氯氮平、奎琉平和利培酮等小分子化合物转移到分析柱中进行二次分离,采用外标法测定氯氮平、奎琉平和利培酮的含量,整个前处理和分析过程仅需18 min。氯氮平在10~1800μg/L浓度范围内相关系数为0.9996,低、中、高浓度的平均回收率分别为118.4%,105.0%和105.4%;奎琉平在3.6~640μg/L浓度范围内相关系数r为0.9997,低、中、高浓度的平均回收率分别为112.8%,101.1%和101.5%;利培酮在0.71~128μg/L浓度范围内相关系数为0.9995,低、中、高浓度的平均回收率分别为100.7%,97.2%和98.8%。结果表明,本方法可极大地提高样品分析效率,快速准确测定人血清中氯氮平、奎琉平和利培酮的含量。     

固体石蜡作粘合剂的纯碳糊电极的电化学活化及其应用于色氨酸的测定

研究了以固体石蜡作粘合剂的纯碳糊电极的电化学活主用于色氨酸直接测定的方法。活化后的电极对色氨酸的吸附能力大大增加，在ＨＡｃ－ＮａＣ溶液中，于＋０．３Ｖ富集后，于＝１．０１Ｖ出峰，用线扫伏安法测定时，二次微分溶电流，与色氨酸浓度在８－１０μｇ／Ｌ范围内成线性；检测限可达２μｇ／Ｌ；２倍的酪氨酸和其它氨基酸不干扰，用于氨基酸酸芭物样品和合成血清样品中色氨酸的测定，相对标准偏差小于２％。     

平头pH电极用于流动注射-电位滴定法测定碱溶液的浓度

以盐酸溶液为滴定剂,采用流动注射-平头pH电极测定强碱(如氢氧化钠溶液)及弱碱(如氨水)溶液的浓度。选择流动注射分析系统的工作参数为:①混合管长度40 cm;②载流盐酸溶液浓度1.027×10-3mol·L-1;③样品进样量310μL;④流速0.82 mL·min-1。结果表明:氢氧化钠和氨水的峰面积、峰高和半峰宽均与其浓度的对数值在一定的范围内呈线性关系。方法用于实际样品分析,滴定灵敏度比手工滴定方法的灵敏度高10倍,测定值的相对标准偏差(n=5)在1.1%~1.8%之间。     

Rapid capillary electrophoretic method for the determination of clozapine and desmethylclozapine in human plasma

A rapid and sensitive high-performance capillary electrophoretic method for the determination of clozapine and its main metabolite desmethylclozapine in human plasma was developed. The separation of the two analytes was carried out in an untreated fused-silica capillary [33 cm (8.5 cm effective length) x 50 microm I.D.] filled with a background electrolyte at pH 2.5 containing beta-cyclodextrin. Baseline separation of clozapine and desmethylclozapine was recorded in less than 3 min. An accurate sample pretreatment by means of solid-phase extraction and subsequent concentration allows for reliable quantitation of clozapine in the plasma of schizophrenic patients under treatment with the drug. The method showed good precision (mean RSD = 4.0%) as well as satisfactory extraction yields (approximately 88%) and a good sensitivity (limit of quantitation = 0.075 microg ml(-1), limit of detection = 0.025 microg ml(-1)).     

Chemiluminescence detection coupled to high-performance frontal analysis for the determination of unbound concentrations of drugs in protein binding equilibrium

High-performance frontal analysis coupled with chemiluminescence detection (HPFA-CL) was developed for the determination of unbound oxacillin concentration in human serum albumin solution. The HPFA system consisted of an ISRP column and a mobile phase of 67 mM potassium phosphate buffer of pH 7.4 and ionic strength of 0.17. The luminol-H2O2-Co2+ system was used in the chemiluminescence detection. An enhancement of luminol chemiluminescence by oxacillin was investigated and employed for determining the concentration of oxacillin in the HPFA eluate. Sample solutions were directly injected onto the column; the drug was eluted as a zonal peak with a plateau region. The unbound drug concentrations were determined by using the height of the plateau. The results agreed with those obtained with conventional ultrafiltration-HPLC method. Good reproducibility was confirmed by the within run and between run RSD < or = 7.4%. HPFA-CL provided a selective method for determination of unbound drug concentration in protein binding equilibrium.     

Glycation alter serum albumin binding of valsartan and nateglinide when studied contemporarily

In this research work, an attempt was made to study alteration in glycated serum albumin binding of valsartan and nateglinide using validated HPLC-UV method and ultrafiltration as in vitro protein binding study model. The chromatographic conditions involved stationary phase Kromasil-100 C18 (100?×?4.6?mm, 3.5?µm) with mobile phase of 10?mM phosphate buffer, acetonitrile, isopropyl alcohol in the ratio of 30:65:5 as isocratic mode at a flow rate of 0.8?mL/min; and the eluent was monitored at 218?nm. Protein precipitation technique was used to extract the drugs from human plasma. The calibration curve was found linear in the range from 50 to 5000?ng/mL. Glycation of human serum albumin was achieved at different concentration levels using D-(+)-glucose and glycated human serum albumin (Gly-HSA) were prepared. Valsartan and nateglinide were not affected the plasma protein binding of each other when studied using HSA. The unbound fraction of valsartan and nateglinide was increased to 10–20 times when spiked with Gly-HSA. About 20% increase in unbound fraction of valsartan was observed when spiked with 10?µg/mL of nateglinide. Furthermore, the unbound fraction of nateglinide was increased nearly to 10% more when incubated with Gly-HSA as compare to recombinant human serum albumin.     

Tudy on drug displacement interactions by capillary electrophoresis-frontal analysis

The interaction between 18-methyl norethindrone and ketoprofen, including the displacement of ketoprofen from human serum albumin binding sites, was investigated by the capillary electrophoresis-frontal analysis method (CE-FA) at room temperature. A very large sample plug was introduced hydrostatically into the capillary (65 cm × 50 μm i.d.; effective length of 35 cm) over 80 s at a height difference of 11 cm. The working conditions for CE-FA separation are as follows: operating voltage, 10 kV; running buffer, 67 mmol·L⁻¹ phosphate, pH 7.4. The unbound ketoprofen concentration was directly measured from the height of the frontal peak. When the concentration of 18-methyl norethindrone was increased from 0 to 200 μmol/L, the unbound ketoprofen concentration was found to increase from 22.4 to 26.4 μmol/L at 100 μmol/L total ketoprofen concentration and from 82.1 to 106.2 μmol/L at 200 μmol/L total ketoprofen concentration. From these data, it may be deduced that the administration of high concentration of 18-methyl norethindrone can displace ketoprofen from its secondary binding site. __________ Translated from Chinese Journal of Chromatography, 2005, 23(2)(in Chinese)     

Simple and Rapid Hollow Fiber Liquid Phase Microextraction Followed by High Performance Liquid Chromatography Method for Determination of Drug-protein Binding

A method was established using hollow fiber-liquid phase microextraction(HF-LPME) followed by high performance liquid chromatography(HPLC) to determine the concentration of the free(unbound) drug in the solution of the drug and protein. Measurements of drug-protein binding ratios and free drug concentrations were then analyzed with the Klotz equation to determine the equilibrium binding constant and number of binding sites for drug-protein interaction. The optimized method allows one to perform the efficient extraction and separation of free drug from protein-bound drug, protein, and other interfering substances. This approach was used to characterize the binding of the anticholinergic drugs atropine sulfate and scopolamine hydrobromide to proteins in human plasma and bovine serum albumin(BSA). The results demonstrate the utility of HF-LPME method for measuring free drug concentrations in protein-drug mixtures and determining the protein binding parameters of a pharmacologically important class of drugs.     

Quantitative determination of clozapine in serum by instrumental planar chromatography

An instrumental planar chromatographic (HPTLC) method for quantitative analysis of clozapine in human serum was developed and validated. Clozapine was extracted with n-hexane-isoamyl alcohol (75:25 v/v). The chromatographic separation was achieved on precoated silica gel F 254 HPTLC plates using a mixture of chloroform and methanol (9:1 v/v) as mobile phase. Quantitative analyses were carried out by densitometry at a wavelength of 290 nm. The method was linear between 10 and 100 ng/spot, corresponding to 0.10 and 1.00 ng/microL of clozapine in human serum after extraction process and applying 10 microL to the chromatographic plates. The method correlation coefficient was 0.999. The intra-assay variation was between 2.10 and 3.33% (n = 5) and the interassay was between 2.67 and 4.44% (n = 9). The detection limit was 0.03 ng/microL, and the quantification limit was 0.05 ng/microL. The method proved to be accurate, with a recovery between 97.00 and 99.00%, with an RSD not higher than 7.22%, and was selective for the active principle tested. This method was successfully applied to quantify clozapine in patient serum samples. In conclusion, the method is useful for the quantitative determination of clozapine in serum.     

Determination of cefquinome in pig plasma and bronchoalveolar lavage fluid by high-performance liquid chromatography combined with electrospray ionization mass spectrometry

The aim of this study was to develop a rapid and sensitive method for the quantification of cefquinome in animal plasma and bronchoalveolar lavage (BAL) fluid using high-performance liquid chromatography combined with electrospray tandem mass spectrometry (LC-ESI-MS/MS). Cefadroxil is used as internal standard. For plasma, the sample preparation includes a simple deproteinization step with a Microcon filter. This allows detecting the unbound cefquinome concentration, which is correlated with the concentration in other body fluids, such as BAL fluid. To be able to detect the total plasma concentration, deproteinization with acetonitrile, followed by a back-extraction of actonitrile with dichloromethane was performed. The BAL fluid is centrifuged to precipitate floating particles. Chromatographic separation is achieved on a PLRP-S column using 0.005% formic acid and methanol as mobile phase. For plasma, good linearity was observed in the range of 5-2500 ng ml(-1) for both the unbound and total concentration. The response in BAL fluid was linear in the range of 4-1000 ng ml(-1). The limit of quantification (LOQ) was set at 5.00 ng ml(-1) for plasma and at 4.00 ng ml(-1) for BAL fluid. The limit of detection (LOD) was 3.12 ng ml(-1) and 0.41 ng ml(-1) for the unbound and total concentration in plasma, respectively, and was 1.43 ng ml(-1) for BAL fluid. The method was shown to be of use in a pharmacokinetic study in pigs, where the correlation between cefquinome concentrations in plasma and BAL fluid of pigs was studied.     

Enantioselective binding analysis of verapamil to plasma lipoproteins by capillary electrophoresis-frontal analysis

Capillary electrophoresis coupled with frontal analysis was applied to the study of enantioselective binding of verapamil (VER) to plasma lipoproteins. The drug-lipoprotein mixed solution, which had been in the binding equilibrium, was hydrodynamically introduced into a non-coated fused-silica capillary. Since VER is positively charged in the neutral run buffer (pH 7.4), the unbound VER enantiomers migrated toward the cathodic end much faster than negatively charged lipoproteins and their bound forms. Once unbound VER migrated apart from lipoprotein, the bound VER was quickly released from the protein to maintain the binding equilibrium. Thus, VER migrated as a zone through the capillary and gave a trapezoidal peak with a plateau region on the electropherogram. The VER concentration in this plateau region was equal to the unbound VER concentration in the initial sample solution. It was found that the bindings of VER to high-density lipoprotein (HDL), low-density lipoprotein (LDL) and oxidized LDL were not site-specific and not enantioselective. Partition-like binding to lipid part of these lipoproteins seemed to be dominant. The total binding affinities of LDL to VER were about seven-times stronger than those of HDL, and the oxidation of LDL by copper ion enhanced the binding affinities significantly.